Finch Therapeutics’ phase 3 trial for a Clostridioides difficile med has been placed on clinical hold by the FDA as the agency requests more information on how the biotech screens the donor-derived microbiome therapy for the virus that causes COVID-19.
That means Finch has paused enrollment in the late-stage trial, dubbed PRISM4, of CP101, the biotech said Tuesday after market close. Shares slipped 11.5% to $7.44 apiece as of 9:38 a.m. ET on Wednesday.